Agentix Corp. (AGTX)
USD 0.05
(-35.88%)
USD 0.05
(-35.88%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.37 Million USD | 0.0% |
| 2021 | 1.34 Million USD | 0.0% |
| 2019 | 121.31 Thousand USD | -9.72% |
| 2018 | 134.37 Thousand USD | -59.87% |
| 2017 | 334.88 Thousand USD | 0.2% |
| 2016 | 334.21 Thousand USD | 65.89% |
| 2015 | 201.46 Thousand USD | -3.55% |
| 2014 | 208.87 Thousand USD | 317.76% |
| 2013 | 50 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 401.13 Thousand USD | 13.43% |
| 2023 Q4 | 353.63 Thousand USD | 0.0% |
| 2023 Q3 | 353.63 Thousand USD | -16.66% |
| 2023 FY | 1.37 Million USD | 0.0% |
| 2023 Q1 | 164.65 Thousand USD | -91.84% |
| 2023 Q2 | 424.33 Thousand USD | 157.71% |
| 2022 Q3 | 186.97 Thousand USD | -23.4% |
| 2022 Q1 | 173.24 Thousand USD | -75.5% |
| 2022 Q2 | 244.1 Thousand USD | 40.91% |
| 2022 Q4 | 2.01 Million USD | 978.94% |
| 2021 Q4 | 706.96 Thousand USD | 226.21% |
| 2021 FY | 1.34 Million USD | 0.0% |
| 2021 Q1 | 1.28 Million USD | 10827.66% |
| 2021 Q3 | 216.71 Thousand USD | -37.07% |
| 2021 Q2 | 344.38 Thousand USD | -73.29% |
| 2020 Q3 | 5032.00 USD | -58.19% |
| 2020 Q4 | 11.79 Thousand USD | 134.48% |
| 2020 Q1 | 30.44 Thousand USD | -15.05% |
| 2020 Q2 | 12.03 Thousand USD | -60.47% |
| 2019 Q1 | 38.89 Thousand USD | -5.17% |
| 2019 FY | 121.31 Thousand USD | -9.72% |
| 2019 Q4 | 35.84 Thousand USD | -16.64% |
| 2019 Q3 | 42.99 Thousand USD | 49.38% |
| 2019 Q2 | 28.78 Thousand USD | -26.0% |
| 2018 Q3 | 25.68 Thousand USD | -49.25% |
| 2018 Q4 | 41.01 Thousand USD | 59.72% |
| 2018 Q1 | 64.54 Thousand USD | -50.09% |
| 2018 Q2 | 50.6 Thousand USD | -21.6% |
| 2018 FY | 134.37 Thousand USD | -59.87% |
| 2017 Q2 | 117.09 Thousand USD | -37.42% |
| 2017 Q1 | 187.11 Thousand USD | 1176.73% |
| 2017 Q3 | 91.78 Thousand USD | -21.62% |
| 2017 Q4 | 129.31 Thousand USD | 40.89% |
| 2017 FY | 334.88 Thousand USD | 0.2% |
| 2016 Q1 | 25.71 Thousand USD | -66.48% |
| 2016 FY | 334.21 Thousand USD | 65.89% |
| 2016 Q4 | 14.65 Thousand USD | -4.51% |
| 2016 Q2 | 40.95 Thousand USD | 59.28% |
| 2016 Q3 | 15.34 Thousand USD | -62.52% |
| 2015 Q1 | 69.24 Thousand USD | 157.58% |
| 2015 Q3 | 58.1 Thousand USD | -5.02% |
| 2015 FY | 201.46 Thousand USD | -3.55% |
| 2015 Q4 | 76.7 Thousand USD | 32.01% |
| 2015 Q2 | 61.17 Thousand USD | -11.67% |
| 2014 Q3 | 51.57 Thousand USD | 0.0% |
| 2014 FY | 208.87 Thousand USD | 317.76% |
| 2014 Q4 | 26.88 Thousand USD | -47.87% |
| 2013 FY | 50 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -2.72% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 72.794% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 95.358% |
| Nascent Biotech, Inc. | 2.22 Million USD | 38.483% |
| Rebus Holdings, Inc. | 664 Thousand USD | -106.59% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 96.318% |
| Qrons Inc. | 643.67 Thousand USD | -113.112% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -252.124% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 97.612% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -230.163% |
| Skye Bioscience, Inc. | 13.54 Million USD | 89.875% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.419% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 72.107% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -424.119% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.398% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 52.961% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 8.665% |
| Mesoblast Limited | 5.9 Million USD | 76.758% |
| Marizyme, Inc. | 19.23 Million USD | 92.87% |
| Genus plc | 147.7 Million USD | 99.071% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 84.375% |
| Pharming Group N.V. | 225.49 Million USD | 99.392% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 33.043% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -2.252% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 83.55% |
| ContraFect Corporation | 56.88 Million USD | 97.589% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 68.885% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 7.236% |
| IMV Inc. | 37.7 Million USD | 96.362% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 50.839% |
| MultiCell Technologies, Inc. | 567.42 USD | -241653.199% |
| ONE Bio Corp. | 6.44 Million USD | 78.712% |
| Accustem Sciences Inc. | 3.74 Million USD | 63.385% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.404% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -157.867% |
| Q BioMed Inc. | 3.43 Million USD | 60.084% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 94.45% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 47.793% |
| Biomind Labs Inc. | 994.18 Thousand USD | -37.978% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.619% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 22.045% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 79.581% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 26.423% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 5587.024% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 91.432% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 25.249% |
| GB Sciences, Inc. | 1.42 Million USD | 3.432% |
| Alpha Cognition Inc. | 9.7 Million USD | 85.866% |
| HST Global, Inc. | 140.9 Thousand USD | -873.519% |
| CSL Limited | 3.44 Billion USD | 99.96% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -21.944% |
| Halberd Corporation | 74.84 Thousand USD | -1732.869% |
| Enzolytics Inc. | 2.17 Million USD | 37.061% |
| Resverlogix Corp. | 12.71 Million USD | 89.209% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 62.425% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.911% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -31.394% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 42.961% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 13.145% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 59.713% |
| AVAX Technologies, Inc. | 7.31 Million USD | 81.235% |
| Zenith Capital Corp. | 8.94 Million USD | 84.661% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.834% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -7774.152% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 44.131% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -699.816% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 28.588% |
| Kadimastem Ltd | 2.41 Million USD | 43.083% |
| Helix BioMedix, Inc. | 1.97 Million USD | 30.44% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 87.377% |
| BioStem Technologies, Inc. | 22.97 Million USD | 94.029% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -655.851% |
| LadRx Corporation | 3.81 Million USD | 64.013% |
| Cell Source, Inc. | 4.32 Million USD | 68.286% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -48.537% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -48.537% |
| NovAccess Global Inc. | 2.46 Million USD | 44.39% |
| Affymax, Inc. | 39.38 Million USD | 96.517% |
| Itoco Inc. | 919.14 Thousand USD | -49.243% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 67.635% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -22.588% |
| Mobile Lads Corp. | 554.54 Thousand USD | -147.366% |
| CytoDyn Inc. | 18.05 Million USD | 92.404% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -5350.181% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -523.304% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 3.383% |
| SYBLEU INC | 160.87 Thousand USD | -752.679% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 24.476% |
| International Stem Cell Corporation | 5.27 Million USD | 73.975% |
| Bioxytran, Inc. | 3.82 Million USD | 64.092% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -2505.82% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -6643.135% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 96.218% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 15.219% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -86.422% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 55.906% |
| Neutra Corp. | 243.82 Thousand USD | -462.608% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 92.142% |
| PureTech Health plc | 144.59 Million USD | 99.051% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 93.305% |
| IXICO plc | 4.7 Million USD | 70.857% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 84.407% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.835% |
| CSL Limited | 3.89 Billion USD | 99.965% |
| Cellectis S.A. | 97.32 Million USD | 98.59% |